Influence of Kurarinol on specific and non-specific cell immunity in patients with chronic hepatitis B.
- Author:
Xi-Bing GU
1
;
Xiao-Juan YANG
;
Dong WANG
;
Yin-Fang ZHU
;
Hong DING
;
Bo ZHANG
;
Yue-Qin XU
;
Hang-Yuan WU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Drug Administration Schedule; Female; Flavonoids; administration & dosage; Hepatitis B, Chronic; drug therapy; immunology; Humans; Immunity, Innate; drug effects; Male; Middle Aged; Silymarin; administration & dosage; T-Lymphocytes, Cytotoxic; drug effects; Young Adult
- From: Chinese Journal of Experimental and Clinical Virology 2009;23(4):288-291
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore influence of Kurarinol on specific and non-specific cell immunity in patients with chronic hepatitis B.
METHODS74 cases of CHB were randomly divided into two groups, 36 cases in treatment group, treated with 600 mg Kurarinol glucose injection, IV, once a day. After one month, Kurarinol capsule was used orally, three times a day for 2 months, 200 mg Silybin Meglumine Tablets orally, three times a day for 3 months. 38 cases in control group, only Silybin Meglumine Tablets was used, method and dosage were the same as treatment group. Compare HBV specific CTL, non-specific CTL, sub-group of T cells, changes of Th1 and Th2, negative conversion rate of HBV DNA and HBeAg of the two groups.
RESULTSIn treatment group, 3 months after treatment with Kurarinol, HBV specific CTL is higher than that before treatment (P < 0.01), it is also higher than that of control after treatment, P < 0.05) . Non-specific CTL is higher than that before treatment (P < 0.05), it is also higher than that of control after treatment (P < 0.01). CD4 is higher than that before treatment (P <0.05), it is also higher than that of control after treatment (P < 0.01), Thl is higher than that before treatment (P < 0.05), it is also higher than that of control after treatment (P < 0.01) . Negative conversion of HBV DNA and HBeAg is higher than that of control (P < 0.01).
CONCLUSIONKurarinol can improve specific and non-specific cell immunity in patients with CHB. It is one of the mechanisms that Kurarinol can clear or inhibit HBV of patients with CHB.
